– UK, Snaith – Croda International Plc (LON: CRDA) today announced the appointment of Julie Kim to its Board as a non-executive director, effective from 1 September 2021.
“I am delighted to welcome Julie to the Croda Board. Julie’s outstanding healthcare sector experience, her strong P&L experience, and commercial R&D and manufacturing knowledge will be of enormous benefit to Croda. She also brings even greater diversity to the Board, in terms of gender, ethnicity, nationality and tenure, as well as her tremendous skills and experiences as a serving executive.” said Board Chair, Anita Frew.
Julie will also be appointed to the Audit, Nomination, and Remuneration Committees.
“Her appointment to the Board supports our strategic plans to build our Life Sciences business and brand. With our focus on drug, vaccine, and crop delivery systems, Julie is ideally placed to help deliver our ambition in these fast-growing markets,” added Anita Frew.
About Julie Kim
Julie Kim has over 25 years of experience in international leadership positions in the healthcare industry and is currently President, Plasma-Derived Therapies at Takeda Pharmaceutical, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Her geographic experience covers both global and regional roles, focused on Europe, Asia, and Latin America. Before joining Takeda in 2019, Julie’s previous executive positions included roles such as Head of International Market Access and Global Franchise Head of multiple therapeutic areas at Shire, Baxalta, and Baxter. Julie also sits on the industry board for the Plasma Protein Therapeutics Association and started her career in healthcare consulting.
For more information : https://www.croda.com/en-gb
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
